HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Postuma, R. B. Articles by Lang, A. E. Search for Related Content PubMed PubMed Citation Articles by Postuma, R. B. Articles by Lang, A. E. Related Collections Nutritional Parkinson's disease/Parkinsonism All Clinical trials

Homocysteine and levodopa

Should Parkinson disease patients receive preventative therapy?

From the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Ontario, Canada.

Address correspondence and reprint requests to Dr. Anthony E. Lang, Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, 399 Bathurst Street, MP11, Toronto, Ontario, Canada M5T 2S8; e-mail: lang{at}uhnres.utoronto.ca

Epidemiologic evidence has linked elevation of serum homocysteine to an increased risk of coronary artery disease, stroke, and dementia. An increase in homocysteine levels in Parkinson disease (PD) recently has been discovered. Although B vitamin status and genetic factors are important modifying influences determining the degree of this elevation, the main cause appears to be therapy with L-dopa. It has been suggested that breakdown of L-dopa by catechol-O-methyltransferase results in increased homocysteine formation. Therefore, there are reasons to suggest that management of PD may render patients at increased risk of stroke, heart disease, dementia, and even accelerated nigral degeneration. At present, no controlled prospective studies have evaluated this phenomenon, although they are ongoing.

Received January 31, 2004. Accepted in final form March 22, 2004.

The authors have developed an investigator-initiated study (mentioned in the article) that has been funded by an unrestricted educational grant from Novartis.

This article has been cited by other articles:

				S. Zoccolella, I. L. Simone, P. Lamberti, V. Samarelli, R. Tortelli, L. Serlenga, and G. Logroscino Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis Neurology, January 15, 2008; 70(3): 222 - 225. [Abstract] [Full Text] [PDF]

				A. Di Rocco, P. Werner, R. B. Postuma, and A. E. Lang VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY Neurology, April 24, 2007; 68(17): 1440 - 1441. [Full Text] [PDF]

				R. B. Postuma, A. J. Espay, C. Zadikoff, O. Suchowersky, W.R.W. Martin, A. -L. Lafontaine, R. Ranawaya, R. Camicioli, and A. E. Lang Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study Neurology, June 27, 2006; 66(12): 1941 - 1943. [Abstract] [Full Text] [PDF]

				M. C. Irizarry, M. E. Gurol, S. Raju, R. Diaz-Arrastia, J. J. Locascio, M. Tennis, B. T. Hyman, J. H. Growdon, S. M. Greenberg, and T. Bottiglieri Association of homocysteine with plasma amyloid {beta} protein in aging and neurodegenerative disease Neurology, November 8, 2005; 65(9): 1402 - 1408. [Abstract] [Full Text] [PDF]

				J. L. Ostrem, G. A. Kang, I. Subramanian, M. Guarnieri, J. Hubble, A. L. Rabinowicz, and J. Bronstein The effect of entacapone on homocysteine levels in Parkinson disease Neurology, April 26, 2005; 64(8): 1482 - 1482. [Full Text] [PDF]